Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer Society Calls For Annual MRI In Women At High Risk For Breast Cancer

This article was originally published in The Gray Sheet

Executive Summary

The American Cancer Society's new 1guidelines on breast cancer screening for the first time recommend annual breast magnetic resonance imaging in patients at high risk

You may also be interested in...



Mammography With Ultrasound Boosts Breast Cancer Detection – Study

Mammography plus ultrasound boosts the detection of breast cancer over mammography alone among women at elevated risk for the disease but also increases the chance for false-positive results, according to a study in the May 14 Journal of the American Medical Association

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel